继发性二尖瓣反流行TEER术中的肺动脉高压:COAPT试验
COAPT试验纳入614例心衰合并中重度及以上继发性二尖瓣反流患者,随机接受MitraClip经导管二尖瓣修复联合GDMT或单纯GDMT。基线PASP≥50 mmHg者2年死亡或心衰住院率更高(68.8% vs 49.1%),但TMVr降低死亡或心衰住院的获益不受基线PASP影响。TMVr较GDMT更显著降低30天PASP,且PASP降低与30天至2年死亡或心衰住院风险降低相关。
要点
- 基线PASP≥50 mmHg与心衰合并继发性二尖瓣反流患者2年死亡或心衰住院风险升高相关。
- TMVr降低死亡或心衰住院的获益不受基线PASP水平影响(交互P=0.45)。
- TMVr较GDMT更显著降低30天PASP,PASP每降低5 mmHg与后续死亡或心衰住院风险降低相关。
核心结论
- 基线PASP升高与心衰合并重度继发性二尖瓣反流患者预后较差相关。
- MitraClip行TMVr较单纯GDMT降低30天PASP及2年死亡或心衰住院率,且不受基线PASP影响。
研究设计与样本
- COAPT试验随机纳入614例心衰合并中重度或重度继发性二尖瓣反流患者,TMVr联合GDMT组302例,单纯GDMT组312例。
- 基线PASP由超声心动图估测,分为显著升高(≥50 mmHg)与未显著升高(<50 mmHg)。
- 本分析纳入528例患者,其中PASP≥50 mmHg者184例(TMVr 82例,GDMT 102例),PASP<50 mmHg者344例(TMVr 171例,GDMT 173例)。
主要发现
- PASP≥50 mmHg组(均值59.1±8.8 mmHg)2年死亡或心衰住院率为68.8%,PASP<50 mmHg组(均值36.3±8.1 mmHg)为49.1%。
- 校正后风险比1.52(95%CI 1.17–1.97,P=0.002),PASP≥50 mmHg者死亡或心衰住院风险更高。
- TMVr较GDMT降低死亡或心衰住院率,不受基线PASP影响(交互P=0.45)。
- TMVr较GDMT更显著降低基线至30天PASP(校正最小二乘均值:−4.0 vs −0.9 mmHg,P=0.006)。
- 30天至2年间,PASP每降低5 mmHg与死亡或心衰住院风险降低相关(校正HR 0.91,95%CI 0.86–0.96,P=0.0009)。
临床怎么用
- 心衰合并重度继发性二尖瓣反流患者应评估PASP,PASP≥50 mmHg提示预后较差。
- 基线PASP升高不应作为排除MitraClip行TMVr的依据,因TMVr获益不受基线PASP影响。
- TMVr后30天PASP降低与后续死亡或心衰住院风险降低相关,可作为疗效评估参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary hypertension worsens prognosis in patients with heart failure (HF) and secondary mitral regurgitation (SMR). OBJECTIVES: This study sought to determine whether baseline pulmonary hypertension influences outcomes of transcatheter mitral valve repair (TMVr) in patients with HF with SMR. METHODS: In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial, 614 patients with HF with moderate-to-severe or severe SMR were randomized to TMVr with the MitraClip plus guideline-directed medical therapy (GDMT) (n = 302) versus GDMT alone (n = 312). Baseline pulmonary artery systolic pressure (PASP) estimated from echocardiography was categorized as substantially increased (≥50 mm Hg) versus not substantially increased (<50 mm Hg). RESULTS: Among 528 patients, 184 (82 TMVr, 102 GDMT) had PASP of ≥50 mm Hg (mean: 59.1 ± 8.8 mm Hg) and 344 (171 TMVr, 173 GDMT) had PASP of <50 mm Hg (mean: 36.3 ± 8.1 mm Hg). Patients with PASP of ≥50 mm Hg had higher 2-year rates of death or HF hospitalization (HFH) compared to those with PASP of <50 mm Hg (68.8% vs. 49.1%; adjusted hazard ratio: 1.52; 95% confidence interval: 1.17 to 1.97; p = 0.002). Rates of death or HFH were reduced by TMVr versus GDMT alone, irrespective of baseline PASP (pinteraction = 0.45). TMVr reduced PASP from baseline to 30 days to a greater than GDMT alone (adjusted least squares mean: -4.0 vs. -0.9 mm Hg; p = 0.006), a change that was associated with reduced risk of death or HFH between 30 days and 2 years (adjusted hazard ratio: 0.91 per -5 mm Hg PASP; 95% confidence interval: 0.86 to 0.96; p = 0.0009). CONCLUSIONS: Elevated PASP is associated with a worse prognosis in patients with HF with severe SMR. TMVr with the MitraClip reduced 30-day PASP and 2-year rates of death or HFH compared with GDMT alone, irrespective of PASP.
引用
- Ben-Yehuda O, Shahim B, Chen S, et al. Pulmonary Hypertension in Transcatheter Mitral Valve Repair for Secondary Mitral Regurgitation: The COAPT Trial. J Am Coll Cardiol. 2020. PMID: 33243380. doi:10.1016/j.jacc.2020.09.609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。